"not for human consumption": A review of emerging designer drugs

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 745-757

  Musselman, Megan E ^a   Hampton, Jeremy P ^b,c  

^a North kansas City Hospital   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c TRUMAN MEDICAL CENTER   (United States)

Author keywords

2C agents; Bromodragonfly; cannabinoids; cathinones; designer drugs; hallucinogens; phenylethylamines; piperazine derivatives; psychostimulants; synthetic drugs

Indexed keywords

1 (8 BROMOBENZOL[1,2 B;4,5 B']DIFURAN 4 YL) 2 AMINOPROPANE; 2C AGENT; ANTIDOTE; BENZOFURAN DERIVATIVE; CANNABINOID; CATHINONE; DESIGNER DRUG; DRONABINOL; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; STREET DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG CONTROL; DRUG INTOXICATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; DRUG USE; HALLUCINATION; HUMAN; SYMPTOM; ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; SUBSTANCE-RELATED DISORDERS;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84903844689     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1424     Document Type: Article

References (85)

1. Madras BK,. Designer Drugs: An Escalating Public Health Challenge. 2012. Available from // www.dfaf.org/webinar/files/designer-drugs.pdf. Accessed July 28, 2013.
2. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM,. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013; 9: 172-8.
3. Snyder SH, Faillace L, Hollister L,. 2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug. Science 1967; 158: 669-70.
4. Arnold C,. The new danger of synthetic drugs. Lancet 2013; 382: 15-6.
5. American Association of Poison Control Centers. Bath Salts. 2013. Available from http://www.aapcc.org/alerts/bath-salts/. Accessed December 30, 2013.
6. American Association of Poison Control Centers. Synthetic Marijuana. 2013. Available from http://www.aapcc.org/alerts/synthetic-marijuana/. Accessed December 30, 2013.
7. Wadley J,. American Teens More Cautious About Using Synthetic Drugs. 2014. Available from http://www.monitoringthefuture.org//pressreleases/13drugpr- complete.pdf Accessed January 28, 2014.
8. Zawilska JB,. "Legal highs"-new players in the old drama. Curr Drug Abuse Rev 2011; 4: 122-30.
9. Title 21 United States Code (USC) Controlled Substances Act. Section 813 Treatment of controlled substance analogues. US: Office of Diversion Control, 1986.
10. Food and Drug Administration Safety and Innovation Act. Scheduling Update. Microgram Bulletin, 2011.
11. Thakur GA, Nikas SP, Makriyannis A,. CB1 cannabinoid receptor ligands. Mini Rev Med Chem 2005; 5: 631-40.
12. Rosenbaum CD, Carreiro SP, Babu KM,. Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8: 15-32.
13. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM,. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-10.
14. Sobolevsky T, Prasolov I, Rodchenkov G,. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010; 200: 141-7.
15. Food and Drug Administration Safety and Innovation Act. United States 2012.
16. Drug Enforcement Administration DoJ. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I. Fed Regist 2014; 79: 1776-80.
17. Dowling G, Regan L,. A method for CP 47, 497 a synthetic non-traditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 253-9.
18. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 2010; 62: 588-631.
19. Di Marzo V, Bifulco M, De Petrocellis L,. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
20. Seely KA, Prather PL, James LP, Moran JH,. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11: 36-51.
21. Grigoryev A, Savchuk S, Melnik A, et al. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1126-36.
22. Schneir AB, Cullen J, Ly BT,. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40: 296-9.
23. Every-Palmer S,. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010; 105: 1859-60.
24. Benford DM, Caplan JP,. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011; 52: 295.
25. Centers for Disease Control and Prevention. Notes from the field: severe illness associated with synthetic cannabinoid use-Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 939.
26. Erowid Vaults. Cannabinoid Receptor Agonists Reports. 2012. Available from http://www.erowid.org/experiences/subs/exp-Cannabinoid-Receptor-Agonists. shtml. Accessed January 4, 2014.
27. Centers for Disease Control and Prevention (CDC). MMWR. Morbidity and Mortality Weekly Reports. Acute Kidney Injury Associated with Synthetic Cannabinoid Use-Multiple States. February, 2012. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm?s-cid=mm6206a1-w2013:93-8. Accessed online August 23, 2013.
28. Wells DL, Ott CA,. The "new" marijuana. Ann Pharmacother 2011; 45: 414-7.
29. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R,. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56: 485-6.
30. Elsohly MA, Slade D,. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78: 539-48.
31. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG,. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76: 245-50.
32. Papanti D, Schifano F, Botteon G, et al. "Spiceophrenia": a systematic overview of "Spice"-related psychopathological issues and a case report. Hum Psychopharmacol 2013; 28: 379-89.
33. Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I,. A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 2013; 405: 8463-74.
34. Simmons J, Cookman L, Kang C, Skinner C,. Three cases of "spice" exposure. Clin Toxicol 2011; 49: 431-3.
35. Gronert GA,. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001; 94: 523-9.
36. Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P,. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 1990; 30: 825-8.
37. Fass JA, Fass AD, Garcia AS,. Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 2012; 46: 436-41.
38. Gibbons S, Zloh M,. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010; 20: 4135-9.
39. Prosser JM, Nelson LS,. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012; 8: 33-42.
40. Erowid Experience Vaults. Bath Salts. 2011. Available from http://www.erowid.org/experiences/subs/exp-MDPV.shtml. Accessed July 31, 2013.
41. Warrick BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, "bath salt," hospital visits reported to poison control centers. Ann Emerg Med 2013; 62: 244-51.
42. James D, Adams RD, Spears R, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 2011; 28: 686-9.
43. Nicholson PJ, Quinn MJ, Dodd JD,. Headshop heartache: acute mephedrone "meow" myocarditis. Heart 2010; 96: 2051-2.
44. Coppola M, Mondola R,. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food." Toxicol Lett 2012; 211: 144-9.
45. Penders TM, Gestring RE, Vilensky DA,. Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 2012; 34: 647-50.
46. Petrie M, Lynch KL, Ekins S, et al. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol 2013; 51: 83-91.
47. Meyer MR, Wilhelm J, Peters FT, Maurer HH,. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397: 1225-33.
48. Peters FT, Martinez-Ramirez JA,. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 2010; 32: 532-9.
49. Dubin WR, Feld JA,. Rapid tranquilization of the violent patient. Am J Emerg Med 1989; 7: 313-20.
50. Lazarus A,. Heatstroke in a chronic schizophrenic patient treated with high-potency neuroleptics. Gen Hosp Psychiatry 1985; 7: 361-3.
51. MacCarthy EP, Bloomfield SS,. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 1983; 3: 193-219.
52. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA,. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993; 94: 608-10.
53. Hysek C, Schmid Y, Rickli A, et al. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 2012; 166: 2277-88.
54. Holzer M,. Targeted temperature management for comatose survivors of cardiac arrest. N Engl J Med 2010; 363: 1256-64.
55. Erowid Vaults. 25I-NBOMe (2C-I-NBOMe). 2012. Available from http://www.erowid.org/chemicals/2ci-nbome/2ci-nbome-effects.shtml. Accessed August 2, 2013.
56. Erowid Vaults. 2C. 1998. Available from http://www.erowid.org/chemicals/ 2ci/. Accessed August 2, 2013.
57. Rose SR, Poklis JL, Poklis A,. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol 2013; 51: 174-7.
58. Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol 2013; 51: 487-92.
59. Zuba D, Sekula K, Buczek A,. 25C-NBOMe-new potent hallucinogenic substance identified on the drug market. Forensic Sci Int 2013; 227: 7-14.
60. Sanders B, Lankenau SE, Bloom JJ, Hathazi D,. "Research chemicals": tryptamine and phenethylamine use among high-risk youth. Subst Use Misuse 2008; 43: 389-402.
61. Cole MD, Lea C, Oxley N,. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci Justice 2002; 42: 223-4.
62. Theobald DS, Maurer HH,. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem Pharmacol 2007; 73: 287-97.
63. Meyer MR, Maurer HH,. Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab 2010; 11: 468-82.
64. Haroz R, Greenberg MI,. New drugs of abuse in North America. Clin Lab Med 2006; 26: 147-64, ix.
65. Taylor RL, Maurer JI, Tinklenberg JR,. Management of "bad trips" in an evolving drug scene. JAMA 1970; 213: 422-5.
66. Rusyniak DE, Sprague JE,. Hyperthermic syndromes induced by toxins. Clin Lab Med 2006; 26: 165-84, ix.
67. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P,. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol 2011; 49: 131-41.
68. Bye C, Munro-Faure AD, Peck AW, Young PA,. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6: 163-9.
69. Campbell H, Cline W, Evans M, Lloyd J, Peck AW,. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6: 170-6.
70. Drug Enforcement Administration DoJ. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Fed Regist 2004; 69: 12794-7.
71. Antia U, Tingle MD, Russell BR,. "Party pill" drugs-BZP and TFMPP. N Z Med J 2009; 122: 55-68.
72. Herndon JL, Pierson ME, Glennon RA,. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol Biochem Behav 1992; 43: 739-48.
73. Staack RF,. Piperazine designer drugs of abuse. Lancet 2007; 369: 1411-3.
74. de Boer D, Bosman IJ, Hidvegi E, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 2001; 121: 47-56.
75. Arbo MD, Bastos ML, Carmo HF,. Piperazine compounds as drugs of abuse. Drug Alcohol Depend 2012; 122: 174-85.
76. Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P,. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol 2008; 46: 802-7.
77. Elliott S, Smith C,. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32: 172-7.
78. Wood DM, Dargan PI, Button J, et al. Collapse, reported seizure-and an unexpected pill. Lancet 2007; 369: 1490.
79. Wood DM, Looker JJ, Shaikh L, et al. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol 2009; 5: 226-9.
80. Bowen JS, Davis GB, Kearney TE, Bardin J,. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983; 249: 1477-9.
81. Erowid Vaults. Bromodragonfly. 1998. Available from http://www.erowid. org/chemicals/bromo-dragonfly/bromo-dragonfly-effects.shtml. Accessed August 1, 2013.
82. Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M,. A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 2009; 183: 91-6.
83. Erowid Vaults. 6-APB. 2011. Available from http://www.erowid.org/ chemicals/6-apb. Accessed August 1, 2013.
84. Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL,. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 2013; 700: 147-51.
85. Chan WL, Wood DM, Hudson S, Dargan PI,. Acute psychosis associated with recreational use of benzofuran 6-(2-Aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol 2013; 9: 278-81.